AQXP...The trial for their flagship drug just failed. They will be presenting the secondary endpoints for this trial with the conference call. The same drug is also being used for another indication, if that too fails, they aren't worth the their money in the bank.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.